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Abstract
In this study, we demonstrate a method for controlling breast cancer cells
adhesion on polyelectrolyte multilayer (PEM) films without the aid of adhesive proteins/ ligands to study the role of tumor and stromal cell interaction on cancer biology. Numerous studies have explored engineering coculture of tumor and stromal cells predominantly using transwell coculture
of stromal cells cultured onto coverslips that were subsequently added to
tumor cell cultures. However, these systems imposed an artificial boundary that precluded cell−cell interactions. To our knowledge, this is the first
demonstration of patterned coculture of tumor cells and stromal cells that
captures the temporal changes in the miRNA signature as the breast tumor develops through various stages. In our study we used synthetic polymers, namely poly(diallyldimethylammonium chloride) (PDAC) and sulfonated poly(styrene) (SPS), as the polycation and polyanion, respectively, to
build PEMs. Breast cancer cells attached and spread preferentially on SPS
surfaces while stromal cells attached to both SPS and PDAC surfaces. SPS patterns were formed on PEM surfaces, by either capillary force lithography (CFL) of SPS onto PDAC surfaces or vice versa, to obtain patterns of breast cancer cells and patterned cocultures of breast cancer and stromal
cells. In this study, we utilized cancer cells derived from two different tumor stages and two different stromal cells to effectively model a heterogeneous tumor microenvironment and emulate various tumor stages. The coculture model mimics the proliferative index (Ki67 expression) and tumor
aggressiveness (HER-2 expression) akin to those observed in clinical tumor samples. We also demonstrated that our patterned coculture model captures the temporal changes in the miRNA-21 and miRNA-34 signature as the breast tumor develops through various stages. The engineered coculture platform lays groundwork toward precision medicine wherein patient-derived tumor cells can be incorporated within our in vitro models to
identify potential pathways and drug treatment regimens for individual patients.

1. Introduction
Breast cancer is one of the leading causes of death worldwide and is forecasted to increase by over 50% from 283 000
in 2011 to 441 000 in 2030 in the United States.1 Recent studies
have demonstrated that tumor microenvironment (TME) plays an
important role in neoplastic transformation, tumor growth and
invasion, and therapeutic resistance.2−4 TME components composed of stromal cells such as fibroblasts, mesenchymal stem
cells (MSCs), and immune cells provides a supportive niche that
promotes the growth and invasion of tumors and is believed to
modulate drug responsiveness.5−7 The intercellular communication between tumor cells and stromal cells occurs via direct contact and paracrine signaling through the recruitment of growth
factors, cytokines, and chemokines.8−10 Together, these modes of
communication are believed to mediate tumor expansion, inva-

sion, metastasis, and angiogenesis. Several studies demonstrate
direct involvement of stromal cells like fibroblasts, normal epithelial cells, and MSCs in progression of tumorigenesis and metastasis.5−7 However, the exact role of different stromal cells in
the TME, their interaction with each other and with the cancer
cell in the progression of tumor has not been fully delineated.
Despite the importance of this cell−cell communication, the current scientific understanding remains limited on the interaction
between the tumor cells and the surrounding cells due to the lack
of appropriate tumor models.
In vivo models have been primarily used to study the involvement of tumor−TME interactions in cancer.11−14 However,
these models are proving to be insufficient, as they do not lend
themselves as readily to rigorous mechanistic manipulations and
quantitative analysis to maximize the information that can be
obtained regarding the dynamics of cell−cell interactions. Xeno-
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graft animal models of human tumors are widely used as in vivo
models for studying cancer metastasis and drug screening.15,16
However, these models do not accurately recreate the various
components of TME and do not allow direct observation of the
tumor during the course of the treatment. There is an increasing interest in the development of in vitro tumor models due to
the ease of manipulation and shorter time frame compared to
an in vivo model.17−20 However, given the complexity of breast
tumor, the challenge of designing an effective in vitro model is
huge. Tumor tissues, the commonly used in vitro model, lack
many characteristics of intact tumor, such as TME and metabolic
demand. Although great effort has been put into developing in
vitro human tumor models as well as 2D and 3D gel culture systems to model TME, significant hurdles remain.19−21 One major
limitation of the current models is that they fail to combine different types of cells, or establish cocultures of tumor cells with
stromal cells in vitro. Random and transwell cocultures are commonly used to study the role of cell−cell interactions in cancer
invasion.22,23 These approaches are limited by poor reproducibility leading to inconsistent results. They also do not account for
the physical contact between the cells that is established when
the tumor cells recruit the stromal cells. Therefore, alternative in
vitro platforms are necessary to study the interaction of cancer
cells with stromal cells.
Recently, in vitro coculture models have been fabricated on
nano/micropatterned surfaces using a variety of microfabrication techniques, ranging from photolithography, microcontact
printing, dip-pen spotting, to inkjet printing.22,24−27 These resulting in vitro patterned coculture models serve as a platform for
studying cell−cell communication in a controlled environment
of spatially defined nano/microscale surface. This addresses the
limitations associated with random coculture and transwell coculture methods by not only providing a robust and reproducible means of recreating cell−cell interactions but also accounting for both direct and paracrine modes of communication. Most
of these microfabrication methods rely on approaches that utilize adhesive proteins for cell attachment and a background surface that resist that are modified later for the attachment of a
second cell type.26−28 Although these techniques allow for recreating the cellular microenvironment, the use of protein substrates adds an artificial component not present in the TME and
does not mimic physiologically relevant interactions. The current
in vitro method is limited due to the requirement of specialized
materials, devices, and extensive expertise.
Herein, we report a robust, inexpensive, protein free method
that utilizes polyelectrolyte multilayers (PEMs) and capillary
force lithography (CFL) to generate patterned coculture models of breast cancer cells and stromal cells. PEMs have been
shown to be excellent candidates for biomaterial applications.28−38 In our study, we used synthetic polymers, namely,
poly(diallyldimethylammonium chloride) (PDAC) and sulfonated poly(styrene) (SPS), as the polycation and polyanion, respectively, to build the multilayers. The choice of SPS and PDAC
was based on previous studies, wherein the latter material was
shown to be resistant to attachment by primary hepatocytes,39
smooth muscle cells,40 and primary neuronal cells,41 while SPS
was cytophilic for all the cell types evaluated. We as well others have previously shown that PEM surfaces utilizing PDAC and
SPS also provide an ability to control the arrangement of multiple cell types with subcellular resolution.24,25,35,39 This technique
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allows the formation of cell patterns with different shapes and
sizes of tunable directional properties, recreating cell−cell interactions in a highly controlled manner. In addition, since CFL is a
variant of soft lithography, this method has key advantages, such
as low cost, high-throughput, and the ability to pattern reproducible macroscopic areas. In this study, we capitalized upon the
differential cell attachment and spreading of breast cancer cells
on different PEM surfaces to engineer patterned cocultures of
breast cancer cells and stromal cells. To demonstrate the translational validity of our platform, we employed two developmentally distinct human breast cell lines for coculture development:
(1) BT474 (HER2+ invasive breast cancer cells to model invasive
ductal carcinoma (IDC)) and (2) 21MT-1 (stable patient-derived
metastatic breast cancer cells isolated from the metastatic pleural effusion to model invasive mammary carcinoma (IMC)). We
also used two different types of stromal cells, mammary epithelial cells (MCF10A) and mesenchymal stem cells (MSCs), to demonstrate the versatility of our platform. Since MCF10A are nontumorigenic cells and MSCs have a significant role in metastasis,
our platform provides an opportunity to study cell−cell interactions in a heterogeneous TME, an inimitable property of cancer
progression. We further illustrated that our in vitro breast tumor
model is capable of staging the breast tumor dynamics and emulating clinical relevant molecular pathways at different stages
of tumor points. For this purpose, we utilized the coculture system developed in this study and demonstrated that our platform
simulated key clinical markers prominently used for tumor diagnosis, including tumor (HER-2) and proliferation (Ki67) markers.
Also our platform mirrored the clinical conditions when probed
for miRNA-21 and miRNA-34 expression. The development of
such in vitro models that recapitulates the in vivo like signaling
in tumor would be desirable to increase the drive toward precision medicine to identify key biomarkers for early diagnosis and
novel therapeutic interventions.
2. Materials And Methods
2.1. Materials. Poly(diallyldimethylammonium chloride) (PDAC) (MW
~ 100,000−200,000) as a 20 wt % solution, sulfonated poly(styrene) sodium salt (SPS) (MW ~ 70 000), sodium chloride, bovine serum albumin (BSA), PKH26 cell staining kit, carboxyfluorescein succinimidyl ester
(CFSE), carboxyfluorescein diacetate succinimidyl ester fluorescent dyes
(CFDSE), alpha-Minimum Essential Medium (α-MEM), sodium bicarbonate (NaHCO3), and cholera toxin were purchased from Sigma-Aldrich
Corporation (St. Louis, MO). Poly(dimethylsiloxane) (PDMS) from the Sylgard 184 silicone elastomer kit (Dow Corning, Midland, MI) was used for
making stamps. DMEM/F12 medium, fetal bovine serum (FBS), horse serum, penicillin−streptomycin, l-glutamine, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), nonessential amino acids, and sodium
pyruvate were purchased from Life Technologies (Gaithersburg, MD).
2.2. Cell Lines and Culture Conditions. Adipose-derived MSCs
and MCF10A cells were purchased from American Type Culture Collection (ATCC). MSCs were maintained in MSCGM (Lonza) supplemented
with growth factors provided with the kit, and MCF10A cells were maintained in phenol red free DMEM/F12 culture medium supplemented with
NaHCO3 (1200 mg/L), 5% horse serum, insulin (10 μg/mL), penicillin G
(100 U/mL), streptomycin (100 μg/mL), l-glutamine (2 mM), EGF (20 ng/
mL), hydrocortisone (500 ng/mL), and cholera toxin (100 ng/mL). HER-2
overexpressed breast cancer cell lines, BT-474 and 21MT-1, were a kind
gift from Dr. Hamid Band (UNMC, Omaha, NE). BT-474 cells were grown
in complete MEM supplemented with 5% FBS, 1% L-glutamine, penicillin G (100 U/mL), streptomycin (100 μg/mL), 20 mM HEPES, nonessential amino acids, and sodium pyruvate (complete α-MEM). 21MT-1 cells
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Figure 1. Breast cancer cells on
polyelectrolyte multilayers. Selective
adhesion of breast cancer cells on
fabricated surfaces was determined
by studying the growth of cells on
PEMs for 5 days. Half TCPS was coated
with (PDAC/SPS)10 and other half with
(PDAC/SPS)10.5 making SPS and PDAC
as the topmost surfaces, respectively.
Adhesion of BT-474 (A) and 21MT-1
(B) cells on PDAC and SPS surfaces
after day 5 of culture show more
attachment of cells on SPS surface.
Scale bar is 500 μm.

were maintained in complete α-MEM, further supplemented with EGF
(12.5 ng/mL) and hydrocortisone (1 ng/mL). All cells were maintained in
the presence of 5% CO2 at 37 °C.
2.3. Cell Adhesion on Polymer Surfaces. Polyelectrolyte multilayers (PEMs) were built on tissue culture polystyrene surface (TCPS) using
layer-by-layer assembly of PDAC and SPS polymers as described earlier.24,25 The concentrations of the PDAC and SPS solutions were 0.02 and
0.01 M, respectively, using repeating unit molecular weight. Both polymers were dissolved in deionized (DI) water with 0.1 M concentration of
sodium chloride followed by filtration through filter paper (pore size <
25 μm). TCPS were treated with oxygen plasma for 5 min using a Harrick plasma cleaner (Harrick Scientific Corporation, Broading Ossining,
NY). The plate was immediately inserted into a Carl Zeiss slide stainer
to carry out the automated layer-by-layer assembly process. Briefly, the
plate was first dipped into the PDAC solution for 20 min followed by
two 5 min washing steps in DI water with agitation. The plate was then
dipped in the SPS solution for 20 min followed by two 5 min washing
steps in DI water with agitation. This process was repeated for either 10
or 10.5 bilayers to form (PDAC/SPS)10 with SPS as a topmost layer and
(PDAC/SPS)10.5 with PDAC as a topmost layer. Prior to cell culture, fabricated surfaces were sterilized overnight under UV. Breast cancer cells
were grown on SPS [(PDAC/SPS)10], PDAC [(PDAC/SPS)10.5] for 5 days.
Cell morphology was assessed by optical microscopic images of the cells
on different surfaces acquired with Axiovert40 Zeiss (Germany) inverted
microscope for 5 days.
2.4. Polydimethylsiloxane (PDMS) Mold Fabrication. PDMS molds
were fabricated by combining the PDMS prepolymer (Sylgard 184, Essex Chemical) and curing agent in an 8:1 w/w ratio. Following vigorous
mixing, the mixture was degassed in a desiccator until bubbles were no
longer visible and cast against a silicon master that contained a pattern
of line channels. The PDMS was cured for 8 h in a 60 °C oven. After cooling to room temperature, a sharp scalpel and tweezers were used to remove the PDMS from the master and cut into stamps capable of fitting
within a well of a six-well plate (approximately 5 mm by 5 mm). Stamps
were cleaned with ultrapure 18 MΩ cm Millipore water and soap, and
then dried with compressed air before use.
2.5. Fabrication of Patterned Surfaces by Capillary Force Lithography (CFL). Line patterns were created on PEMs built on TCPS surfaces
using CFL. Patterned PDMS molds (discussed previously) were activated
with oxygen plasma for 1 min and placed pattern-down on the PEMcoated substrate. Slight pressure was applied to the mold to ensure good
contact. Ten μL of the polymer solution that possesses a charge opposite to the last layer of the PEM was injected into the channel openings
(i.e., PDAC for [(PDAC/ SPS)10] or SPS for [(PDAC/SPS)10.5]). The solution
was drawn through the channels by capillary action, and the mold was
undisturbed until solvent evaporation was completed. Once finished, the
PDMS was carefully removed along the channel patterns. The surface
was rinsed with DI water to remove excess polymer and dried at room

temperature. To generate more complex grid patterns for potential tricultures, CFL was repeated on the patterned substrate, positioning the
PDMS mold at a 90-degree rotation.
2.6. Characterization of Patterns. Generated patterns were visualized using 6-carboxyfluorecein succinimidyl ester (CFSE), rhodamine B,
and negatively charged carboxylated polystyrene microparticles. Fabricated surfaces were incubated with CFSE or rhodamine B or microparticles for 10 min at room temperature, followed by three washes with DI
water. Fluorescent and phase contrast images of patterns were observed
and captured using Axiovert40 Zeiss inverted microscope (Germany).
2.7. Cell Staining and Coculture. For visualization of cell patterns,
breast cancer cells and stromal cells were prestained prior to seeding on
patterned substrates. Two different cell types were distinguished from
one another by staining with carboxyfluorescein diacetate succinimidyl
ester (CFDSE) dye (green) and PHK26 dye (red), respectively. Briefly, cells
were trypsinized and washed with medium without serum. Cells were
subsequently incubated in 10 μg/ mL CFDSE in PBS solution at a concentration of 1 × 107 cells/mL or in 2 × 106 M PKH26 in diluent C at a
concentration of 1 × 107 cells/ mL for 10 min at room temperature. Both
staining reactions were quenched with the addition of an equal volume
of serum and washed three times with medium. After a final wash, the
cell pellet was suspended in medium, and 0.5 × 106 breast cancer cells
were seeded. On the following day, 0.2 × 106 MSCs or MCF10As were
seeded. Fluorescent images of the cells patterns were acquired with Axiovert40 Zeiss (Germany) inverted microscope before and after coculture.
2.8. Western Blotting. Cells were washed three times with ice coldphosphate buffered saline (PBS) and scraped in RIPA buffer (100 mM
Tris, 5 mM EDTA, 5% NP40, pH-8.0) containing protease inhibitors cocktail (PIC) and phenylmethylsulfonyl fluoride (PMSF) followed by 10 min
incubation on ice with intermittent vortexing. Clear cell lysate from all
coculture systems was obtained by centrifugation at 10 000 rpm for 10
min at 4 °C and stored at −80 °C until use. Protein concentration was
determined using Coomassie Plus Assay reagent purchased from Pierce
(Rockford, IL). An am amount of 10 μg of total protein was separated by
7.5% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon P membranes (Millipore, Ballerica, MA) using transfer buffer (25 mM
Tris, 192 mM glycine, 10% methanol). Membranes were blocked with 5%
skimmed milk for 3 h at room temperature (RT) thereafter membranes
were incubated with primary antibodies for overnight at 4 °C. Anti-HER-2
(1:1000), anti-Ki67 (1:1000), or anti-GAPDH (1:4000) primary antibodies were used followed by incubation with corresponding horse peroxidase-conjugated secondary antibodies (1:5000) at room temperature
(RT) for 1 h. Signal was detected using ECL and exposure to ECL Hyperfilm (Pierce, Rockford, IL). Densitometry was performed using Image Studio Lite Software ver 4.0 (LI-COR Biosciences).
2.9. miRNA Isolation and qRT-PCR. Total miRNAs were isolated
from cells using the miRNeasy isolation mini-kit (Qiagen). Quality and
quantity of isolated miRNAs were tested using a ND-1000 spectropho-
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Figure 2.
Characterization
of patterns.
(A) Schematic overview
for employing PEMs and
CFL to create patterned
coculture platform of
breast cancer cells and
stromal cells. First, 10.5
bilayers of PDAC and
SPS were deposited to
a substrate using layerby-layer deposition
to generate PDAC as
a topmost layer. SPS
polymer was deposited
through channels of
PDMS stamp using
capillary force to
generate polymer
patterns. Breast cancer
cells were seeded on
patterned surfaces
followed by seeding of
stromal cells on day 3
to generate patterned
coculture.
(B) Dimensions of PDMS
mold employed.
(C) Characterization
of polymer patterns
generated using
CFL. Patterns were
characterized using
green dye CFSE (i); red
dye rhodamine B (ii).
Scale bar is 200 μm.
(D) Complex grid
patterns visualized
with CFSE (i, iii) and
rhodamine B (ii, iv). Scale
bar is 500 μm.

tometer (NanoDrop Technologies, Wilmington, DE). The Mir-X miRNA
First-Strand Synthesis Kit (Clontech) was used for converting miRNAs into
cDNA to enable specific miRNAs to be quantified by real-time PCR. The
SYBR Advantage qPCR Premix (Clontech) and mRQ 3′ (Clontech) primer
were then used in real-time qPCR, along with miRNA-specific 5′ primers, to quantify miR-21 and miR-34a in the cDNA. Sequences for miR-21
and miR-34a 5′ primers were: 5′-TAGCTTATCAGACTGATGTTGA-3′ and 5′TGGCAGTGTCTTAGCTGGTTGT-3′ respectively. Quantitative PCR for miR21 and miR-34a was performed in epgradient S Mastercycler (Eppendorf) using a program: denaturation at 95 °C for 10 s, followed by 45
cycles of 95 °C for 5 s and 60 °C for 20 s. At the end, one cycle for dissociation curve was performed at 95 °C for 60 s, followed by 55 °C for 30 s
and 95 °C for 30 s. Data were analyzed using comparative delta−delta Ct
method described earlier for which an additional qPCR was performed
using U6 snRNA controls provided in SYBR Advantage qPCR Premix kit.42

3. Results
3.1. Breast Cancer Cells on Polyelectrolyte Multilayers. To investigate the effects of PEM films on breast can-

cer cells, we assessed the response of breast cancer cells over
continuous culture (Figure 1). For this purpose we utilized
poly(diallyldimethylammonium chloride) (PDAC) and poly(4- styrenesulfonic acid) (SPS) as the polycation and polyanion, respectively, to build the PEM films. PDAC and SPS are strong polyelectrolytes, resulting in smooth, homogeneous and stable PEM films
suitable for cellular studies.43−45 The combination of PDAC and
SPS has been widely employed to construct PEMs, although less
work on cell adhesion has been done on this pair of polyelectrolytes than on other pairs such as poly(acrylic acid)/polyallylamine, PAA/PAH, or the more biomolecular poly(glutamic acid)/
polylysine, PGA/PLL. The choice of PDAC was based on our previous studies, wherein this material was shown to be cell-resistant
for primary hepatocytes, neurons, and breast cancer cells.24,25,42
Recent study has demonstrated that PEMs using PDAC and SPS
resulted in quasi-spherical cell clusters and attributed this differential cell adhesion due to the presentation of surface charges
in different conditions.35 The thin films used for the cell studies
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Figure 3. Patterned culture of breast cancer cells on PEMs. Breast cancer
cells patterns on day 1 and day 3 of cultures. On day 3 of culture, breast
cancer cells form clear patterns distinct from surround background. Scale
bar is 500 μm.

were free of adhesive proteins or ligands. We employed two developmentally distinct human breast cell lines for coculture development: (1) BT474 (HER2+ invasive breast cancer cells) and
(2) 21MT-1 (stable patient-derived metastatic breast cancer cells
isolated from the metastatic pleural effusion). We have previously shown that breast cancer cells, BT-474 and SKBr3 cells, attached more on SPS surfaces than PDAC.42 Figure 1 compares
the morphology of breast cancer cells on PDAC and SPS surfaces.
For the direct comparison of the cell adhesion, we coated half
the TCPS with (PDAC/SPS)10 and other half with (PDAC/SPS)10.5
making SPS and PDAC as the topmost surfaces, respectively.
Both BT-474 and 21MT-1 had higher attachment on SPS surfaces
compared to PDAC surfaces demonstrating the preferential attachment of breast cancer cells on SPS over PDAC. We utilized
this differential cell adhesion to develop patterned coculture of
breast cancer cells with stromal cells.
3.2. Patterned Culture of Breast Cancer Cells on PEMs.
Figure 2A shows a schematic diagram of overall strategy we
used to develop patterned coculture. For patterning with CFL,
thin layers of polymers were deposited using layer-by-layer assembly and a liquid prepolymer of PDMS was cast against a silicon master to prepare a PDMS mold. PDMS is excellent material for mold preparation because of its high permeability for air
to permeate out of the mold during molding process, an important characteristic for high resolution patterning. In addition, PDMS chemical inertness, low surface tension, favorable
mechanical and optical properties, and simple manufacturing
make it compatible with CFL methods, yielding robust microstructures over substrates regardless of patterning materials.
Since CFL relies on naturally occurring capillary force without
use of any external force, it offers a number of advantages in fabricating geometry-controllable, robust micro and nanostructures
over a large area. Dimensions of patterns used for this study are
shown in Figure 2B. Patterning of polymer occurs when a liquid
wets capillary tubes and moves forward with lowering of free
energy (Figure 2C). Fabricated patterns were then characterized
with fluorescent dyes (negatively charged CFSE and positively
charged rhodamine), and negatively charged microparticles. The
charges of the dye and microparticles mediate the ionic interaction on the surface, with the negatively charged macromolecules

Figure 4. Patterned cocultures of tumor cells with stromal cells. BT- 474
and 21MT-1 breast cancer cells were stained with green dye CFDSE prior
to seeding cells on patterns. Stromal cells, MSCs and MCF10A, were
stained with red dye, PKH26 dye. Left panel shows monochrome fluorescent images of BT-474 cells (A, D) and 21MT-1 cells (G, J). Middle panel
shows monochrome fluorescent images of MSCs (B, H) and MCF10A (E,
K). Right panel represents merged image of BT-474/MSCs (C); BT-474/
MCF10A (F); 21MT-1/MSCs (I); 21MT-1/MCF10A (L). Scale bar is 500 μm.

deposited on PDAC surfaces while the positively charged macromolecules deposited on SPS surfaces. Our data illustrated that
the SPS/PDAC micropatterns were successfully created on glass
substrates with good coverage and well-defined edges (Figure
2C). To further demonstrate the ability to recreate more complex
microenvironment for cell−cell interaction, we fabricated intricate patterns by repeating CFL, positioning the PDMS mold at a
90-degree rotation. The stained patterns with CFSE and rhodamine shows formation of complex patterns indicating the PDAC
and SPS regions (Figure 2D).
Figure 3 illustrates the attachment of breast cancer cells on
PDAC and SPS patterns after one and 3 days of culture. When
presented with the patterned surface, both BT-474 and 21- MT1
adhered preferentially on the SPS regions resulting in patterns
of breast cancer cells. On day 1, breast cancer cells attached
preferentially on the SPS regions resulting in cell patterns. The
breast cancer patterns attached and maintained their morphology for the first few days, but by day 7 began to detach from
the PEM surfaces due to overcrowding (data not shown). We further optimized the media composition and identified 1:1 ratio
of breast cancer cells and MSCs or MCF10A media as the best
culture conditions for the coculture platform (Supporting Information Figure 1).
3.3. Patterned Cocultures of Tumor Cells with Stromal
Cells. Figure 4 illustrates patterned cocultures of breast cancer cells with stromal cells on PEM surfaces. We employed two
developmentally distinct human breast cell lines for coculture
development: (1) BT474 (HER2+ invasive breast cancer cells to
model IDC) and (2) 21MT-1 (stable patient-derived metastatic
breast cancer cells isolated from the metastatic pleural effu-
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Figure 5. Coculture
emulates tumor
progression.
(A) Upper panel
shows representative
immunoblot image
of protein expression
of Ki67 in BT-474
and 21MT-1 breast
cancer cells (BCCs)
cocultured with MSCs
and MCF10A cells.
Lower panel shows
densitometry analysis
of bands normalized
with respective BCCs
monocultures. ***p
< 0.001 vs BCCs
monoculture.
(B) Upper panel
shows representative
immunoblot image of
protein expression of
HER-2 in BT-474 and
21MT-1 breast cancer
cells cocultured with
MSCs and MCF10A
cells. Lower panel
shows densitometry
analysis of bands
normalized with
respective BCCs
monocultures. ***p
< 0.001 vs BCCs
monoculture.

sion to model IMC). We also used two different types of stromal cells, mammary epithelial cells (MCF10A) and mesenchymal
stem cells (MSCs), to demonstrate the versatility of our platform.
Since MCF10A are nontumorigenic cells and MSCs have a significant role in metastasis, our platform provides an opportunity to study cell−cell interactions in a heterogeneous TME, an
inimitable property of cancer progression. The preferential attachment of breast cancer cells to SPS surfaces enabled the use
of this system as a template for patterned cocultures with stromal cells on synthetic PEM surfaces. To distinguish two cell populations in patterned coculture system, breast cancer cells were
stained with CFDSE dye (green) and stromal cells were stained

with PKH26 dye (red). Fluorescence images of breast cancer cells
and stromal cells showed distinct patterns of breast cancer cells
on day 4 in coculture (Figure 4). We examined the reusability of
these patterns. The cells were removed from the patterns with
trypsin-EDTA and washed with PBS to ensure that the cells were
completely removed from the patterned surfaces. A fresh batch
of breast cancer cells was subsequently seeded onto the reused
patterns and resulted in the formation of the patterns again
(data not shown).
3.4. Coculture Emulates Tumor Progression. To further validate our model at functional level, we investigated the changes
in key clinical markers prominently used for tumor diagnosis, in-
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cluding tumor and proliferation in our coculture platform (Figure 5). Western blot analysis was performed on the coculture of
breast cancer cells BT-474 and 21MT-1 with MSC and MCF10A
to study tumor progression and proliferative rates using HER2
and Ki67 as respective markers with mono culture of breast cancer cells and MSCs as controls. Previously, MSCs have been demonstrated to induce increase proliferation and tumor growth
of breast tumor.8−10 Since, MCF10A are normal mammary epithelial cells, no change in proliferation is anticipated. Our data
showed a significant upregulation of Ki67 protein expression in
cocultures of breast cancer cells with MSCs, while no significant
change was observed in cells in transwell coculture, and monocultures of breast cancer cells and MSCs indicating that the direct
cell−cell contact is key to this phenomenon (Figure 5A). Furthermore, no significant increase in Ki67 expression was observed in
breast cancer cells in coculture with MCF10A cells, suggesting
the role of MSCs in tumor progression. Furthermore, a significant upregulation of HER-2 protein expression was observed in
cocultures of breast cancer cells with MSCs (Figure 5B) but not in
transwell cocultures of breast cancer cells/MSCs and cocultures
of breast cancer cells/MCF10A. Such changes are indicative of a
net increase in cell growth (vs. apoptosis) and development of
an aggressive tumor that would be consistent with the morphologic transition in both the IDC and IMC stages. In the comparison between BT474/MSCs coculture (IDC-like) and 21MT1/MSCs
coculture (IMC-like), HER-2 expression was significantly higher in
the IMC model. These results demonstrate that the breast cancer
cells in the IMC model indicated increase in tumor malignancy,
which is similar to the transition observed in the clinical testing
of IDC and IMC tumor samples.46−52
3.5. Coculture Emulates miRNA Profiles of Clinical Conditions. Microarray analysis on BT474/MSC and 21MT1/MSC coculture models showed that several miRNAs, including miRNA-21
and miRNA-34a, were regulated (data not shown). Clinical studies have shown that miRNA-21 is upregulated in all pathways in
breast cancer and plays an important role in deregulating many
genes leading to the development of breast cancer.53−55 miRNA34a, a tumor suppressor miRNA, was reported to have significant
influence on cell cycle, proliferation, migration, invasion, and selfrenewal in breast cancer cells.56−58 qRT-PCR on BT474/MSCs coculture and 21MT1/MSCs coculture was performed to validate
the microarray data and profile the miRNA expression in the two
breast cancer models with monoculture of breast cancer cells and
MSCs as controls (Figure 6). The expression levels of miR-21 were
increased in both coculture models while the expression levels of
miR-34a were decreased in IDC coculture model compared to a
monoculture of breast cancer cells. This data is representative of
the miRNA expression trend observed in clinical breast tumor tissues. The coculture model mimics breast cancer progression and
shows stage-specific miRNA expression patterns.
4. Discussion
Breast cancer continues to be a major focus of medical research due to its extensive socioeconomic impact. The majority of the studies directly target tumor cells; however, the clinical
success of these studies to develop mechanistic understanding and antitumor therapies remains limited. Recently, cancer cell−stromal cell communications are strongly believed to
play a significant role in cancer initiation, progression, and drug
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Figure 6. Coculture emulates miRNA profiles of clinical conditions. (A)
Relative gene expression of miR-21 in BT-474 and 21MT-1 breast cancer cells (BCCs) cocultured with MSCs after normalization with respective BCCs monocultures. *p < 0.05 vs BCCs monoculture; ***p < 0.001 vs
BCCs monoculture. (B) Relative gene expression of miR- 34a in BT-474
and 21MT-1 breast cancer cells cocultured with MSCs after normalization with respective BCCs monocultures. **p < 0.01 vs BCCs monoculture.

responsiveness.5−7 Here, we report the development of patterned
cocultures of breast cancer cells and stromal cells as in vitro
models of breast tumors. Our in vitro platform is capable of recreating the dynamics of various stages of breast tumors. Communication between breast cancer cells and stromal cells has
been widely recognized to play an important role in cancer initiation, promotion, progression, and development of resistance
to treatment.5−7 Cancer cells maneuver the TME to favor cancer
progression and metastasis by influencing stromal cells and the
ECM.59−62 On the other hand, the stromal cells such as MSCs and
epithelial cells carry the local tissue architectural cues and influence the cancer behavior.63−65 Animal experiments have made
a significant contribution to understanding human diseases, including breast cancer.11−14 However, they lack the ability to intercept communication signals and to create snapshots of different tumor stages in order to better predict the effectiveness
of treatment strategies in clinical settings. The in situ coculture
model developed in this study allows interaction between stromal cells (MSC, MCF10A) and tumor cells in a controlled microenvironment and emulates the temporal progression of the
diseases, especially the evolution of genetic morphosis. The significant advantages of our platform are (1) the protein-free cellculture environment reduces nonspecific function; (2) the physical contact between stromal cells and cancer cells established
in our platform facilitates to investigate the role of direct cell−
cell interaction in tumor biology; and (3) the cancer−stromal cell
interaction can be controlled by pattern dimensions to emulate
different stages of a breast tumor. This platform further demon-
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strates the capability of our in vitro coculture model to recapitulate the trends observed in clinically relevant biomarkers (HER-2
and Ki67 expression).46−52 We also demonstrate that our coculture platform mimics the miRNA- 21 and miRNA-34a expression observed in clinical breast tumor samples.56−58,66−68 To our
knowledge, no study has specifically investigated and demonstrated the role of stromal cells in regulation of miRNA expression in breast cancer. Our in vitro platform replicates the clinically observed trend with markers implicated to tumor stages
and biology.
The advent of new approaches and diagnostic tests has led
to validating Ki67 and HER-2 as important prognostic and predictive markers. Ki67 is a nuclear nonhistone protein, and an
antigen associated with cell proliferation and a strong correlation has been found between the percentage of cells positive
for Ki67 and nuclear grade, age, and mitotic rate in breast cancer.46,47 Cheang and co-workers demonstrated that immunopanel
of HER2 and Ki67 can segregate the luminal A and B subtypes of
breast cancers.48 This clinical study indicated that a differential
Ki67 expression was suitable to discriminate between the subtypes with higher expression classified as luminal B breast cancers having worse prognosis for both breast cancer recurrence
and survival while lower expression classified as luminal A tumors. Numerous studies have shown that breast cancers overexpressing Ki67 in more than 20%−50% of the cells are at high risk
of developing recurrent disease, showing a statistically significant
correlation with clinical outcome, such as disease-free survival
or overall survival.46−49 HER2 plays an important role in promoting oncogenic transformation and tumor growth.50−52 25%−30%
of the breast cancer patients overexpress HER2 protein, and this
overexpression is correlated with a poor clinical outcome.50−52
Clinical studies have demonstrated that tumors with HER2 protein and gene overexpression showed a high concordance between the primary tumors and their metastases (97%).69 Majority of these studies have been performed in clinical patient
tissues and animal models, however these are time-consuming
and complicated to use the data for identifying the subtypes of
the cancer. Our in vitro platform mimicked the clinical observations when the tumor cells were in direct contact with MSCs,
where in the Ki67 and HER-2 protein expression was significantly
(p < 0.001) higher compared to the tumor cells alone. Furthermore, this effect was not observed when the tumor cells were
in direct contact with MCF10A cells. This demonstrates that our
in vitro models can better represent the human tumors to investigate the underlying mechanisms of tumor progression between different subtypes and understand the role of stromal
cells in the dynamic and heterogeneous behavior of cancers that
mediates tumor progression and influences treatment response
and outcomes. Our platform also paves way to Precision Medicine focusing on understanding complex interactions that are
encountered but hard to dissect in clinical human samples while
minimizing analysis times.
Recent studies indicate that microRNA (miRNA) is an effective
biomarker for a variety of diseases, including breast cancer.53−58
MiRNA are a new class of RNAs that are involved in regulating
mRNA expression at the post-transcriptional level and have an
active role in gene regulation.70,71 Several of them are uniquely
produced in cancer cells where they upregulate (or downregulate) the synthesis of certain proteins, leading to the formation of
tumors. Microarray-based profiling of tumor samples from breast
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cancer patients found that miRNA-21 was consistently upregulated in several types of breast cancer, suggesting a role for this
miRNA in mammary tumor initiation or progression.66 Additionally, miRNA-21 has also been identified as a marker for breast
cancer and predictor of stage with higher expression at later
stages of breast cancer.53−55 We demonstrated that miRNA-21
expression is upregulated in both breast cancer cells cocultured
with MSCs. Interestingly, we observed miRNA-21 expression
was significantly higher in the 21MT1/MSCs coculture (IMC-like)
compared to BT474/MSCs coculture (IDC-like). miRNA-21 has
been found to be significantly higher in breast tumors with high
proliferation index, advanced tumor staging, node involvement,
and aggressive phenotype.53−55 Our coculture demonstrates a
similar phenotype wherein we observe significantly higher Ki67
expression in both IMC-like and IDC-like models which is indicative of high proliferation index. Huang and co-workers showed
that the miRNA-21 expression is correlated with HER- 2 upregulation and identified that miRNA-21 induces HER2- induced
cancer cell invasion and miRNA-21 overexpression is a key phenotype in HER-2-positive breast cancer patients.72 These clinical
results were emulated in our in vitro platform where we showed
that the HER-2 expression is significantly upregulated in the coculture model which is indicative of advanced tumor staging and
aggressive phenotype similar to the transition observed in the
clinical testing of IDC and IMC tumor samples.56−58,66−68 MiRNA34a is a potent tumor suppressor and abrogation of miRNA-34a
function could contribute to aberrant cell proliferation, leading
to cancer development.56−58 Kato and co-workers demonstrated
that low expression of miRNA-34a has been found in breast cancer cells.73 Roth and co-workers showed that circulating levels of
miRNA-34a correlate with the presence of overt metastases in
breast cancer patients.74 Peurala et al. have shown that miRNA34a acts as a tumor suppressor and when expressed exerts an independent effect for a lower risk of recurrence or death in breast
cancer.75 This study observed low expression of miRNA-34a in
about 32% and high expression in about 25% of the tumors.
High miRNA-34a expression was correlated with an aggressive
phenotype of breast tumors with high tumor grade and high
proliferation rate of the tumors (IMC-like) while low expression
of miRNA-34a was correlated with early stages of breast cancer
(IDC-like). This indicates that miRNA-34a profile signature varies with the stage of the breast cancer and this also might explain the discrepant data on the miRNA- 34a expression in diverse tumor entities that have been described. miRNA-34a has
been reported to be downregulated in nonsmall cell lung carcinomas, pancreas tumor cell lines, colon carcinomas and primary neuroblastomas.76,77 In contrast, Dutta and co-workers observed a high incidence of miRNA-34a overexpression in various
tumor types.78 Consistent with the data of Peurala et al.,75 we detected varying miRNA-34a levels in our coculture platform depending on the source of the cells. BT474/MSCs coculture (IDClike) had a significant downregulation of miRNA-34a expression
while 21MT1/MSCs coculture (IMC-like) had a slight upregulation of miRNA-34a expression, thus indicative of the emulation
of the corresponding tumor stages observed in clinical samples.
In summary, we demonstrated an innovative approach to engineer coculture of breast cancer and stromal cells, using the
polyelectrolyte multilayers (PEM films) and capillary force lithography (CFL). This approach has several advantages over the
method used by other groups. The advantages include its high
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fidelity, ease of duplication, ability to provide topographical features, ability to print a variety of molecules with nanometer resolution and without the need for dust-free environments and
harsh chemical treatments. We have provided evidence that our
platform emulates the different stages of the breast tumor by
modeling IDC-like and IMC-like systems. To validate the mimicry
of the clinical conditions, we demonstrated that the proliferative
index (Ki67 expression) and tumor aggressiveness (HER-2 expression) in our coculture platform is similar to the clinical samples. Furthermore, we also demonstrated that our model provides the ability to capture the temporal change in the miRNA
signature as the breast tumor develops through various stages.
The key advantage of our coculture in situ breast tumor model
is the ability to tailor the transitions between different stages
of breast cancer by recreating and controlling the cell−cell interactions in play as the breast tumor progresses. This platform
provides a robust system to compare the temporal changes in
miRNA expression to segregate the cancer subtypes. In the future, this platform will provide an important tool for unlocking
some of the intricacies of the miRNA-mediated molecular influences on early breast progression and potentially target specific
processes to effectively stop breast cancer progression. The engineered coculture platform also lays groundwork toward precision medicine where in patient-derived tumor cells can be incorporated within our in vitro models to identify potential pathways
and drug treatment regimens for individual patients.
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Supplementary Information

Supplementary Figure 1: Optimized culture conditions for the co-culture platform. (A)
Upper panel, representative immunoblot shows expression of HER-2 as a marker for breast
cancer cell to optimize media condition for co-culture of breast cancer cells with MSCs. Lower
panel, densitometry analysis of bands shows no significant change in HER-2 expression when
breast cancer cells (MEM/HE) and MSCs (MSCGM) media was used in 1:1 ratio. (B) Upper
panel, representative immunoblot shows expression of HER-2 as a marker for breast cancer cell
to optimize media condition for co-culture of breast cancer cells with MCF10A. Lower panel,
densitometry analysis of bands shows no significant change in HER-2 expression when breast
cancer cells (MEM/HE) and MCF10A (DMEM/F12) media was used in 1:1 ratio.

